- Home
- MA vs JNJ Comparison
MA vs JNJ Comparison
Compare MA & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MA | JNJ |
|---|---|---|
| Founded | 1966 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.1B | 449.6B |
| IPO Year | 2006 | 1944 |
Fundamental Metrics
Financial Performance| Metric | MA | JNJ |
|---|---|---|
| Price | $575.77 | $204.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 25 | 15 |
| Target Price | ★ $652.40 | $209.27 |
| AVG Volume (30 Days) | 2.8M | ★ 7.5M |
| Earning Date | 01-29-2026 | 01-21-2026 |
| Dividend Yield | 0.60% | ★ 2.54% |
| EPS Growth | 18.23 | ★ 71.26 |
| EPS | ★ 15.64 | 10.35 |
| Revenue | $31,474,000,000.00 | ★ $92,149,000,000.00 |
| Revenue This Year | $19.84 | $6.61 |
| Revenue Next Year | $12.59 | $5.33 |
| P/E Ratio | $36.80 | ★ $19.75 |
| Revenue Growth | ★ 15.60 | 5.08 |
| 52 Week Low | $465.59 | $140.68 |
| 52 Week High | $601.77 | $215.19 |
Technical Indicators
Market Signals| Indicator | MA | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 56.72 | 46.80 |
| Support Level | $573.50 | $200.91 |
| Resistance Level | $589.67 | $208.98 |
| Average True Range (ATR) | 8.36 | 2.81 |
| MACD | -0.04 | -0.76 |
| Stochastic Oscillator | 55.48 | 36.39 |
Price Performance
Historical ComparisonAbout MA Mastercard Incorporated
Mastercard is the second-largest payment processor in the world, having processed close to $10 trillion in volume during 2024. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.